Search results for "antineoplastic"

showing 10 items of 2217 documents

Intrinsic Expression of Drug Resistance-Associated Factors in Meningiomas

2001

Meningiomas, commonly benign tumors, rarely display aggressive behavior by recurrences and invasion. In addition to surgery, irradiation is beneficial for recurrent, atypical, and malignant meningiomas. The role of chemotherapy, however, remains controversial, although there is evidence that meningiomas respond well to adjuvant chemotherapy. A major obstacle in chemotherapy remains drug resistance with reduced cellular drug accumulation through membrane efflux pumps, drug detoxification, and alterations in drug target specificity. In 84 classic, atypical, and malignant meningiomas, the immunohistochemical expression profile of P-glycoprotein (P-gp), multidrug resistance-associated protein (…

MaleDrugHistologyAdolescentmedia_common.quotation_subjectmedicine.medical_treatmentAntineoplastic AgentsDrug resistancePathology and Forensic MedicineMeningeal Neoplasmsotorhinolaryngologic diseasesmedicineHumansMetallothioneinneoplasmsAgedmedia_commonAged 80 and overChemotherapybiologybusiness.industryTopoisomeraseDrug detoxificationMiddle AgedImmunohistochemistryNeoplasm Proteinsnervous system diseasesMedical Laboratory TechnologyDrug Resistance NeoplasmDisease ProgressionCancer researchbiology.proteinImmunohistochemistryFemaleEffluxMeningiomabusinessApplied Immunohistochemistry & Molecular Morphology
researchProduct

Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy

2008

Cancer continues to be one of the major health and socio-economic problems worldwide, despite considerable efforts to improve its early diagnosis and treatment. The identification of new constituents as biomarkers for early diagnosis of neoplastic cells and the discovery of new type of drugs with their mechanistic actions are crucial to improve cancer therapy. New drugs have entered the market, thanks to industrial and legislative efforts ensuring continuity of pharmaceutical development. New targets have been identified, but cancer therapy and the anti-cancer drug market still partly depend on anti-mitotic agents. The objective of this paper is to show the effects of KAR-2, a potent anti-m…

MaleDrugmedicine.medical_specialtyGeneral Mathematicsmedia_common.quotation_subjectCancer therapyGeneral Physics and AstronomyAntineoplastic AgentsNerve Tissue Proteinsanti-mitotic drugReviewVinblastineMicrotubulesModels Biologicalanti-mitotic proteinTubulinCell Line TumorNeoplasmsKAR-2Biomarkers TumormedicineAnimalsHumanscancerRats WistarIntensive care medicinemedia_commonTPPP/p25Dose-Response Relationship Drugbusiness.industryGeneral EngineeringCancermedicine.diseaseRatsDrug marketbioavailabilitybusinessPhilosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences
researchProduct

Lanreotide Therapy vs Active Surveillance in MEN1-Related Pancreatic Neuroendocrine Tumors2 Centimeters.

2019

Abstract Purpose Pancreatic neuroendocrine tumors (pNETs) are frequent in multiple endocrine neoplasia type 1 (MEN1) syndrome. They are usually not surgically treated unless larger than 1 to 2 cm or a growth rate > 0.5 cm per year. Somatostatin analogues represent one of the main therapeutic options in pNETs, but they have never been prospectively investigated in MEN1-related pNETs. The aim of this study was to prospectively evaluate the effectiveness of lanreotide in patients with MEN1-related pNETs < 2 cm. Methods MEN1 patients with 1 or more pNETs < 2 cm of maximal diameter were considered. Study design was prospective observational, comparing patients treated with l…

MaleEndocrinology Diabetes and MetabolismClinical BiochemistryNeuroendocrine tumorsLanreotideBiochemistryGastroenterologychemistry.chemical_compoundEndocrinologyactive surveillance lanreotide MEN1 pancreatic neuroendocrine tumors somatostatin analoguesProspective StudiesProspective cohort studyMultiple endocrine neoplasiasomatostatin analoguesMiddle AgedPrognosisTumor BurdenNeuroendocrine TumorsSomatostatinMEN1Disease ProgressionFemalelanreotideSomatostatinAdultmedicine.medical_specialtyAntineoplastic Agentspancreatic neuroendocrine tumorPeptides CyclicYoung AdultInternal medicinemedicineMultiple Endocrine Neoplasia Type 1HumansMEN1Watchful WaitingAgedCentimeterpancreatic neuroendocrine tumorsbusiness.industryBiochemistry (medical)active surveillancemedicine.diseasePancreatic NeoplasmsEndocrinologychemistryactive surveillance; lanreotide; MEN1; pancreatic neuroendocrine tumors; somatostatin analoguesTumor progressionCase-Control StudiesbusinessFollow-Up StudiesThe Journal of clinical endocrinology and metabolism
researchProduct

Inhibition of cancer growth by resveratrol is related to its low bioavailability.

2002

The relationship between resveratrol (RES) bioavalability and its effect on tumor growth was investigated. Tissue levels of RES were studied after i.v. and oral administration of trans-resveratrol (t-RES) to rabbits, rats, and mice. Half-life of RES in plasma, after i.v. administration of 20 mg t-RES/kg b.wt., was very short (e.g., 14.4 min in rabbits). The highest concentration of RES in plasma, either after i.v. or oral administration (e.g., 2.6 +/- 1.0 microM in mice 2.5 min after receiving 20 mg t-RES/kg orally), was reached within the first 5 min in all animals studied. Extravascular levels (brain, lung, liver, and kidney) of RES, which paralleled those in plasma, were always1 nmol/g f…

MaleEndotheliumMelanoma ExperimentalBiological AvailabilityVascular Cell Adhesion Molecule-1ResveratrolPharmacologyIn Vitro TechniquesIntegrin alpha4beta1medicine.disease_causeBiochemistrychemistry.chemical_compoundMiceOral administrationPhysiology (medical)StilbenesmedicineCell AdhesionAnimalsTissue DistributionRats Wistarchemistry.chemical_classificationKidneyReactive oxygen speciesCell growthAntineoplastic Agents PhytogenicBioavailabilityRatsMice Inbred C57BLmedicine.anatomical_structurechemistryBiochemistryLiverResveratrolRabbitsOxidative stressCell DivisionHalf-LifeFree radical biologymedicine
researchProduct

4-Epidoxycycline: an alternative to doxycycline to control gene expression in conditional mouse models

2004

Since the pioneering work by Gossen and Bujard in 1992 demonstrating the usefulness of the Escherichia coli derived tet resistance operon for regulating gene expression a large collection of doxycycline-controlled transgenic mice has been established. Gene switching in eukaryotic tissue culture cells or mice requires administration of tetracycline, anhydrotetracycline or doxycycline to efficiently inactivate the transactivator protein tTA (TET-OFF system) or alternatively to activate the reverse transactivator protein rtTA (TET-ON system). However, the antibiotic activity of doxycycline can create an imbalance of the intestinal flora, resulting in diarrhoea and in a smaller number of animal…

MaleGenetically modified mouseReceptor ErbB-2TransgeneBiophysicsAdministration OralMice NudeAntineoplastic AgentsBreast NeoplasmsMice TransgenicBiologyPharmacologyBiochemistryMiceTransactivationCell Line TumorGene expressionmedicineAnimalsMolecular BiologyDoxycyclineRegulation of gene expressionDose-Response Relationship DrugOncogeneStereoisomerismCell BiologyRatsGene Expression Regulation NeoplasticDisease Models AnimalTreatment OutcomeTetracyclinesCell cultureDoxycyclineImmunologyNIH 3T3 Cellsmedicine.drugBiochemical and Biophysical Research Communications
researchProduct

Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?

2009

Background/Aim: Patients with an occult hepatitis B virus (HBV) infection undergoing deep immunosuppression are potentially at risk of HBV reactivation. In order to assess whether a polymerase chain reaction (PCR) assay for HBV DNA in serum could be used to predict the reactivation of an occult HBV infection, we performed a retrospective study in a cohort of Sicilian patients with oncohaematological diseases. Methods: We studied by a highly sensitive ad hoc nested PCR for serum HBV DNA 75 HBsAg-negative oncohaematological patients requiring chemotherapy. Results: Thirty-three patients (44%) were HBV seronegative (anti-HBc and anti-HBs negative) and 42 patients (56%) were HBV seropositive (a…

MaleHBsAgHepatitis B virusHepatitis C virusAntineoplastic AgentsComorbiditymedicine.disease_causePolymerase Chain ReactionSerologyCohort StudiesBlood serumHepatitis B ChronicPredictive Value of TestsRecurrenceRisk FactorsmedicineHumansSeroconversionRetrospective StudiesHepatitis B virusHepatologybusiness.industryvirus diseasesHepatitis BMiddle Agedmedicine.diseasedigestive system diseasesItalyHematologic NeoplasmsImmunologyDNA ViralFemaleVirus ActivationbusinessNested polymerase chain reactionLiver international : official journal of the International Association for the Study of the Liver
researchProduct

Modification of hepatic drug-metabolizing enzymes in rat fed naturally occurring allyl sulphides

1994

1. The effects of feeding allyl sulphides to rat (2000 ppm of the diet for 15 days) were investigated on various microsomal hepatic drug-metabolizing enzymes by their immunochemical detection and catalytic activity. 2. Allyl sulphides provoked a temporary dietary restriction, which enhanced the microsomal level of P450 and the activities of NADH-cytochrome c reductase and p-hydroxybiphenyl UDP-glucuronyltransferase (UDPGT 2), and lowered the activities of p-nitrophenol hydroxylase (PNPH), N-nitrosodimethylamine demethylase (NDMAD), laurate omega-hydroxylase (LAH) and glutathione S-transferase (GST). Therefore, pair-fed animals were used as a more relevant control for the dietary effects of …

MaleHealth Toxicology and MutagenesisImmunoblottingAllyl compoundAntineoplastic Agents[SDV.BID]Life Sciences [q-bio]/BiodiversitySulfidesReductaseToxicologyBiochemistryEating03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIMMUNOCHIMIECytochrome P-450 Enzyme SystemAnimalsDisulfidesGlucuronosyltransferaseRats WistarEpoxide hydrolaseAnticarcinogenGlutathione Transferase030304 developmental biologyEpoxide HydrolasesPharmacologychemistry.chemical_classification0303 health sciencesDose-Response Relationship DrugbiologyChemistryBody WeightCytochrome P450Organ SizeGeneral MedicineGlutathioneDietRatsAllyl CompoundsEnzymeLiverBiochemistryTOXICOLOGIE030220 oncology & carcinogenesisMicrosomes Liverbiology.proteinMicrosomeRAT[SDV.BID] Life Sciences [q-bio]/Biodiversity
researchProduct

Cardiovascular events and intensity of treatment in polycythemia vera.

2013

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascula…

MaleHematocritRECURRENT THROMBOSISlaw.inventionAged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Thrombosis; Hematocrit; Phlebotomy; Medicine (all)LEUKOCYTOSISPolycythemia veraRandomized controlled trialPhlebotomylawhemic and lymphatic diseasesESSENTIAL THROMBOCYTHEMIAClinical endpointHydroxyureaPolycythemia Vera Secondary ProphylaxisESSENTIAL THROMBOCYTHEMIA RECURRENT THROMBOSIS RISK-FACTOR HEMATOCRIT MANAGEMENT LEUKOCYTOSIS PREVENTION DIAGNOSIS EFFICACY WARFARINPolycythemia Veramedicine.diagnostic_testMedicine (all)Hazard ratioGeneral MedicineMiddle AgedCombined Modality TherapyHematocritCardiovascular DiseasesFemalemedicine.medical_specialtyrandomized trial; polycythemia veraAntineoplastic AgentsCardiovascular eventDIAGNOSISWARFARINRISK-FACTORInternal medicineMANAGEMENTmedicineHumansMyelofibrosisAdverse effectAgedbusiness.industryThrombosisPhlebotomyJanus Kinase 2EFFICACYmedicine.diseasePREVENTIONSurgeryPolycythemia Vera Cardiovascular event hematocritSettore MED/15 - MALATTIE DEL SANGUEbusinessFollow-Up Studies
researchProduct

Intra-arterial idarubicin_lipiodol without embolization can provide prolonged complete response in hepatocellular carcinoma: A case report.

2020

International audience; Hepatocellular carcinoma is the fourth leading cause of cancer death. For unresectable intermediate-stage hepatocellular carcinoma, the standard treatment is transarterial chemoembolization. To date, the overall survival at three years remains low, and there is currently no consensus about the best anticancer agent and optimal treatment regimen. We report the case of a hepatocellular carcinoma patient with a vascular contraindication to embolization who achieved a complete response after four intra-arterial infusions of idarubicin emulsified with lipiodol. The patient maintained his response over a three-year period without any hepatocellular carcinoma treatment, dem…

MaleHepatocellular carcinoma[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatmentGastroenterologyEthiodized Oil0302 clinical medicineMESH: Infusions Intra-ArterialMESH: Liver NeoplasmsPharmacology (medical)EmbolizationMESH: Carcinoma HepatocellularComplete responseMESH: Treatment OutcomeMESH: AgedStandard treatmentLiver Neoplasms[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences3. Good healthTreatment OutcomeOncology030220 oncology & carcinogenesisHepatocellular carcinomaLipiodol030211 gastroenterology & hepatologymedicine.drugmedicine.medical_specialtyIntra-arterial therapyCarcinoma HepatocellularAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesMESH: Ethiodized OilInternal medicinemedicineHumansInfusions Intra-ArterialIdarubicinContraindicationAgedMESH: Humansbusiness.industryMESH: Idarubicinmedicine.diseasedigestive system diseasesMESH: MaleRegimenMESH: Antineoplastic AgentsbusinessIdarubicin
researchProduct

Risk of chemotherapy-associated liver injury (CALI) in PNPLA3 p.148M allele carriers: Preliminary results of a transient elastography-based study

2019

Liver steatosis is one of the side effects of chemotherapy. The PNPLA3 p.I148M, TM6SF2 p.E167K and MBOAT7 p.G17E variants represent genetic determinants for progressive liver diseases. Here, we investigate their association with chemotherapy-associated steatosis.Prospectively, we recruited 87 patients undergoing systemic chemotherapy for gastrointestinal cancers. Hepatic fat (controlled attenuation parameter, CAP) and liver stiffness (LSM) were measured non-invasively before the initiation of chemotherapy (T0) and after at least two (T1) and four cycles (T2). Genetic variants were genotyped using allelic discrimination assays.In the final dataset (n = 60) patients demonstrated the following…

MaleHeterozygotemedicine.medical_specialtymedicine.medical_treatmentAntineoplastic AgentsGastroenterology03 medical and health sciences0302 clinical medicineFat accumulationInternal medicinemedicineHumansGenetic Predisposition to DiseaseAdiponutrinProspective StudiesAlleleeducationAllelesTriglyceridesAgedLiver injuryChemotherapyeducation.field_of_studyPolymorphism GeneticHepatologybusiness.industryGastroenterologyMembrane ProteinsLipaseMiddle Agedmedicine.diseaseFatty LiverLiver030220 oncology & carcinogenesisElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologySteatosisTransient elastographybusinessAcyltransferasesTM6SF2Digestive and Liver Disease
researchProduct